# Cosmos Health Accelerates Growth with Facility Upgrades and Strategic Partnership for AMBITASOL Production

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Cosmos Health continues upgrading its Cana facility and signs a contract with Pharmex to produce 300K bottles of the antiseptic drug AMBITASOL 1L....

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L - Cosmos Health (NASDAQ:COSM)

CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has completed t…

# Cosmos Health Accelerates Growth with Facility Upgrades and Strategic Partnership for AMBITASOL Production

In a strategic move aimed at bolstering its operational capabilities, Cosmos Health is making significant strides in both its manufacturing infrastructure and product development portfolio. The company has recently expanded its facility upgrade program at Cana Laboratories, a decision that underscores its commitment to enhancing operational efficiency and production quality. This initiative not only aims to streamline existing processes but also…